Vista Capital Partners Inc. purchased a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 1,103 shares of the company’s stock, valued at approximately $1,276,000.
Several other hedge funds have also added to or reduced their stakes in LLY. McElhenny Sheffield Capital Management LLC grew its position in Eli Lilly and Company by 8.3% during the 3rd quarter. McElhenny Sheffield Capital Management LLC now owns 469 shares of the company’s stock worth $543,000 after acquiring an additional 36 shares during the last quarter. BankPlus Trust Department increased its stake in Eli Lilly and Company by 3.7% in the 3rd quarter. BankPlus Trust Department now owns 6,025 shares of the company’s stock worth $6,971,000 after purchasing an additional 216 shares during the period. Aberdeen Group plc lifted its position in Eli Lilly and Company by 1.9% in the third quarter. Aberdeen Group plc now owns 695,689 shares of the company’s stock valued at $804,968,000 after purchasing an additional 12,871 shares during the last quarter. EagleClaw Capital Managment LLC lifted its position in Eli Lilly and Company by 3.7% in the third quarter. EagleClaw Capital Managment LLC now owns 1,837 shares of the company’s stock valued at $2,126,000 after purchasing an additional 65 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its position in Eli Lilly and Company by 14.3% in the third quarter. Moors & Cabot Inc. now owns 26,106 shares of the company’s stock valued at $30,206,000 after purchasing an additional 3,266 shares during the last quarter. 82.53% of the stock is owned by institutional investors.
Eli Lilly and Company Trading Up 0.0%
NYSE LLY opened at $1,444.05 on Monday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a 50 day simple moving average of $1,242.25 and a two-hundred day simple moving average of $1,110.30. The stock has a market cap of $1.36 trillion, a P/E ratio of 46.87, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s revenue was up 38.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $7.02 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.
Eli Lilly and Company Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.
Insider Activity at Eli Lilly and Company
In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a report on Tuesday, September 15th. BMO Capital Markets reiterated an “outperform” rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. Argus upped their price target on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a report on Friday, October 30th. Bank of America reissued a “buy” rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Guggenheim raised their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,416.64.
View Our Latest Report on Eli Lilly and Company
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
